The FDA has approved bevacizumab for use in combination with carboplatin and paclitaxel, followed by bevacizumab monotherapy, for the treatment of women with advanced ovarian cancer following initial surgical resection.
More From BioPortfolio on "FDA Approves Bevacizumab as Frontline Ovarian Cancer Treatment After Surgery"